This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.1 (sulfite oxidase deficiency) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | SUOX deficiency, Isolated sulfite oxidase deficiency, Molybdenum cofactor deficiency (MoCD), MOCS1/MOCS2/GPHN deficiency, disorders of sulfur-containing amino acid metabolism |
| C. Adult onset | Very low likelihood of first presenting in adulthood — almost all patients present within days to weeks of birth with acute neonatal encephalopathy and are diagnosed in infancy; very rare cases of a mild form of isolated SUOX deficiency (late-onset) presenting in childhood to adolescence have been reported; first diagnosis in adulthood is extremely exceptional. |
| 1. History | 1967 first report of isolated sulfite oxidase deficiency (Duran et al.) → 1978 establishment of the concept of molybdenum cofactor deficiency → 1995 cloning of the SUOX gene → 1995–2000 identification of the MOCS1/MOCS2/GPHN genes → 2010 first compassionate use of fosdenopterin (cPMP) in MoCD-A → 2021 FDA approval of fosdenopterin. |
| 2. Causes | Isolated SUOX deficiency: mutation of the SUOX gene (12q13.2) → sulfite oxidase deficiency → accumulation of sulfite, S-sulfocysteine and taurine. MoCD: variants of the MOCS1 (6p21.2)/MOCS2 (5q11)/GPHN (14q23.3) genes → defective synthesis of molybdenum cofactor (Moco) → combined deficiency of SUOX, xanthine dehydrogenase (XDH) and aldehyde oxidase (AOX). |
| 3. Genetics | Isolated SUOX deficiency: autosomal recessive, SUOX gene (12q13.2). MoCD: autosomal recessive. Type A (MOCS1 variants, about 50–60% of all MoCD), type B (MOCS2 variants, about 30–40%), type C (GPHN variants, rare). More than 200 variants reported worldwide. Type A: defect in the cPMP pathway (treatable). |
| 4. General epidemiology | A very rare disease. Isolated SUOX deficiency: about 100 or fewer cases reported worldwide (as of 2024). MoCD: about 200 or fewer cases reported worldwide. Overall incidence: estimated at about 1:100,000–1:200,000. No sex or ethnic differences. A very small number of cases have been reported in Korea. |
| 5. Pathophysiology | Excess accumulation of sulfite → neurotoxicity: ① Sulfite cleaves the disulfide bonds of cystine to form S-sulfocysteine → NMDA receptor overactivation → excitotoxicity. ② Inhibition of brain energy metabolism (inhibition of pyruvate dehydrogenase). ③ Mitochondrial dysfunction. MoCD type B and isolated SUOX: excess xanthine and hypoxanthine → nephrolithiasis (kidney stones). ④ Abnormal development of brain neural structures → cystic encephalomalacia. |
| 6. Symptoms | Acute neonatal encephalopathy (most cases): intractable seizures within days to weeks of birth (no response to anticonvulsants before diagnosis), dystonia, feeding refusal and feeding difficulty, decreased consciousness. Afterward: hypotonia → spastic quadriplegia, severe mental and motor developmental delay. Additional in MoCD type B: low uric acid and kidney stones (xanthine stones). Mild isolated SUOX (rare): only intellectual disability and seizures in childhood. |
| 7. Signs | Early neonatal seizures (multifocal or clonic). Spastic cerebral palsy develops after hypotonia. Brain MRI/CT: extensive restricted diffusion in the cortex, basal ganglia and thalamus, cystic encephalomalacia. Urine: elevated S-sulfocysteine, positive sulfite (fresh urine test strip). Decreased serum uric acid (MoCD). Elevated urine xanthine (MoCD type B). |
| 8. Screening | Newborn screening (NBS): currently not included in NBS in most countries; measurement of urine S-sulfocysteine and taurine is at the research stage. When clinically suspected: neonatal intractable seizures → fresh urine sulfite dipstick. Quantification of urine S-sulfocysteine (LC-MS/MS). Serum/urine uric acid (hypouricemia suggests MoCD). |
| 9. Diagnosis | Quantification of urine S-sulfocysteine (the key indicator for definitive diagnosis; undetectable in normal individuals, markedly elevated in patients). Positive fresh urine sulfite dipstick (fresh urine is essential because the metabolite is unstable). Decreased serum uric acid (in MoCD, xanthine dehydrogenase is also deficient → accumulation of hypoxanthine and xanthine → inability to produce uric acid). Elevated urine xanthine and hypoxanthine (MoCD). SUOX/MOCS1/MOCS2/GPHN gene NGS panel. Brain MRI: cystic encephalomalacia, abnormal signal in the basal ganglia and cortex. |
| 10. Treatment | Isolated SUOX deficiency: no curative treatment at present; supportive care (anticonvulsants, nutritional support, rehabilitation). Low-sulfur diet (cystine restriction → reduction of sulfite precursors) — reported in some cases but with limited effect. MoCD-A (MOCS1 deficiency): fosdenopterin (cPMP, Nulibry) intravenous administration — FDA approval in 2021 as a rare pediatric disease drug; replaces cPMP exogenously to restart Moco synthesis. MoCD-B: cyclopyranoxime (CPCA) and others under investigation; no standard curative treatment at present. All forms: for seizures → levetiracetam, phenobarbital; vitamin support (vitamin B6, inositol, etc., experimental). |
| 11. Prognosis | Mostly very poor. Isolated SUOX deficiency and MoCD-B: after acute neonatal encephalopathy, spastic cerebral palsy, severe intellectual disability and intractable seizures persist. Untreated MoCD-A: median age at death about 2.4 years, 1-year survival about 70–77%. With fosdenopterin treatment (MoCD-A): reduced seizures (within 2 weeks of starting treatment), seizure freedom and improved neurodevelopment have been reported — early treatment (within 5 days of birth) is decisive. With no effective treatment for MoCD-B and isolated SUOX, the prognosis is extremely poor. |
| 12. Prevention | Primary: genetic counseling (recurrence risk 25%), prenatal/preimplantation genetic testing (PGT-M) offered. Secondary: inclusion of S-sulfocysteine in NBS is under discussion; in newborns with a family history, urine S-sulfocysteine and sulfite testing immediately after birth. Tertiary: in MoCD-A, early administration of fosdenopterin (within days of birth) to minimize neurological damage; integrated management by a multidisciplinary team (neurology, nephrology, nutrition, rehabilitation). |
| 13. References | Veldman A et al. Pediatrics. 2010 … and 9 other papers |
The history of sulfite oxidase deficiency began in 1967 when Duran et al. first reported abnormally elevated S-sulfocysteine and taurine in urine and sulfite excess in a patient with neonatal seizures and encephalopathy. This report was the first to suggest that deficiency of sulfite oxidase (SUOX) can cause neonatal neurological disease.
In 1978, Johnson et al. in the United Kingdom established the concept of "molybdenum cofactor deficiency (MoCD)," distinct from isolated SUOX deficiency, in which a defect in molybdenum cofactor (Moco) synthesis causes simultaneous loss of function not only of SUOX but also of xanthine dehydrogenase (XDH) and aldehyde oxidase (AOX). Moco is a cofactor commonly required at the active center of all three of these enzymes.
In 1995, Weidemann et al. cloned the SUOX gene on chromosome 12 (12q13.2), and at about the same time Russe et al. identified MOCS1, the first causative gene of MoCD. Subsequently, genes of the Moco synthesis pathway such as MOCS2 (1997) and GEPH (GPHN, 2001) were identified in turn. MoCD is classified by gene into type A (MOCS1), type B (MOCS2) and type C (GPHN).
The breakthrough in treatment came in 2010 in Germany, when cyclic pyranopterin monophosphate (cPMP) was first administered for compassionate use to a neonate with MoCD-A, and seizure freedom and improved neurodevelopment were reported. The principle of cPMP is exogenous replacement of the deficient intermediate of the type A Moco synthesis pathway. After subsequent clinical trials, fosdenopterin (Nulibry, synthetic cPMP) was approved in 2021 by the FDA as a treatment designated for a rare pediatric disease. In 2024, an international consensus guideline on diagnosis and management for isolated SUOX deficiency and all forms of MoCD was published in the Journal of Inherited Metabolic Disease, and diagnosis and treatment are being standardized.
Sulfite oxidase deficiency is broadly divided into two forms: isolated SUOX deficiency and molybdenum cofactor deficiency (MoCD).
Isolated sulfite oxidase deficiency: Caused by pathogenic variants of the SUOX gene located on chromosome 12 (12q13.2). The SUOX gene encodes the sulfite oxidase protein, which is located in the mitochondrial intermembrane space and catalyzes the oxidation of sulfite (SO₃²⁻) to sulfate (SO₄²⁻). Molybdenum cofactor (Moco) is essential for this reaction. When enzyme activity is lost owing to SUOX variants, sulfite accumulates and toxic metabolites such as S-sulfocysteine and taurine are produced, causing central nervous system damage.
Molybdenum cofactor deficiency (MoCD): Caused by variants of genes (MOCS1, MOCS2, GPHN) responsible for several steps of the Moco synthesis pathway. Moco is the active-center cofactor of three enzymes: SUOX, XDH and AOX. Loss of SUOX function due to Moco deficiency is the same as in isolated SUOX deficiency, but MoCD is characterized by an additional biochemical abnormality in which loss of XDH function causes accumulation of xanthine and hypoxanthine and decreased uric acid production. MoCD-A (MOCS1 variants): defect in the first step of Moco synthesis (GTP → cPMP conversion). MoCD-B (MOCS2 variants): defect in cPMP → MPT conversion. MoCD-C (GPHN variants): defect in the final step, MPT → Moco (extremely rare).
Both isolated SUOX deficiency and MoCD follow an autosomal recessive mode of inheritance.
Isolated SUOX deficiency: The SUOX gene is located on chromosome 12 (12q13.2), is about 49 kb in size and is composed of 3 exons. More than 30 pathogenic variants have been reported worldwide, and most are missense variants. Reports are concentrated in Middle Eastern, Mediterranean and Asian lineages, and founder mutations have been identified in some ethnic groups.
MoCD-A (MOCS1 variants): The MOCS1 gene is located on chromosome 6 (6p21.2) and encodes two functional proteins (MOCS1A, MOCS1B). It accounts for about 50–60% of all MoCD and is the only form treatable with fosdenopterin.
MoCD-B (MOCS2 variants): The MOCS2 gene is located on chromosome 5 (5q11) and accounts for about 30–40% of all MoCD. There is currently no effective curative treatment.
MoCD-C (GPHN variants): The GPHN (gephyrin) gene is located on chromosome 14 (14q23.3). It is extremely rare, and the gephyrin protein has a dual role in the final step of Moco synthesis and in anchoring synaptic inhibitory receptors, so the clinical features differ.
In all forms, heterozygous carriers are clinically asymptomatic, and the risk of recurrence in siblings is 25%.
Sulfite oxidase deficiency (isolated SUOX deficiency and MoCD) is a very rare neurometabolic rare disease with an incidence of about 1 in 100,000–200,000 births worldwide. As of 2024, about 100 or fewer cases of isolated SUOX deficiency and about 200 or fewer cases of MoCD have been reported in the literature worldwide.
The distribution of types within MoCD is about 50–60% for type A (MOCS1), about 30–40% for type B (MOCS2), and type C (GPHN) is extremely rare. It occurs worldwide regardless of sex and ethnicity, although higher frequency has been reported in certain populations owing to founder mutation effects (some groups in the Middle East and North Africa). Only a very small number of cases have been reported in Korea, and it must always be included in the differential diagnosis of neonates with intractable neonatal seizures.
These diseases are currently not included in newborn screening (NBS) in most countries, so there is often a delay of days to weeks in diagnosis after neonatal onset. The effectiveness of fosdenopterin treatment (MoCD-A) is strongly associated with early administration (within 5 days of birth), so diagnostic delay directly affects treatment efficacy.
The core pathophysiology of sulfite oxidase deficiency is toxic accumulation of sulfite in the brain.
Mechanism of sulfite neurotoxicity: When sulfite accumulates in cells owing to SUOX deficiency, it reacts with the disulfide bonds (-S-S-) of cysteine to form S-sulfocysteine (SSC). SSC is structurally similar to glutamate and acts as an excitotoxic substance that overactivates NMDA receptors. NMDA receptor overactivation → sharp rise in intracellular Ca²⁺ → mitochondrial dysfunction → neuronal apoptosis → extensive brain damage occurs.
Impaired energy metabolism: Sulfite inhibits pyruvate dehydrogenase, blocking the entry of glucose into the TCA cycle and reducing cellular energy production. This is particularly fatal for the energy-dependent developmental processes of the neonatal brain.
Structural brain damage: The combined action of excitotoxicity and energy deficiency causes extensive cell death in the cerebral cortex, basal ganglia, thalamus and hippocampus, forming multicystic encephalomalacia. The cerebellum tends to be relatively preserved early on. On MRI diffusion-weighted imaging (DWI) it appears as early extensive restricted diffusion and then progresses to cystic change.
Additional mechanism in MoCD: Xanthine and hypoxanthine accumulate owing to XDH deficiency. Xanthine is highly insoluble and can form kidney stones (xanthine stones). Because no uric acid is produced, serum uric acid levels are extremely low (hypouricemia). This biochemical finding is an important indicator for distinguishing MoCD from isolated SUOX deficiency.
The clinical symptoms of sulfite oxidase deficiency present as acute encephalopathy in the neonatal period, leading to progressive spastic cerebral palsy and severe neurodevelopmental delay.
Acute neonatal presentation: Intractable seizures begin within days to weeks of birth (usually 1–7 days after birth). The seizures are multifocal or myoclonic and often do not respond to common anticonvulsants (phenobarbital, phenytoin, levetiracetam). Feeding difficulty due to feeding refusal and a reduced gag reflex is prominent. Decreased consciousness and hypotonia accompany it. When the urine is fresh at this stage, a peculiar odor (sulfur-containing compounds) may be noted.
Subsequent course: Seizures continue in infancy and in some patients decrease spontaneously, but complete resolution is rare. Hypotonia changes over time into spastic quadriplegia or dystonia. Visual and auditory responses decline. Severe mental and motor developmental delay progresses, and language, cognitive and motor functions hardly develop.
Additional symptoms of MoCD: In MoCD-B, urinary stone symptoms due to xanthine stones (hematuria, abdominal pain, urinary tract infection) may occur. Decreased serum uric acid (the opposite of gout) is characteristic.
Mild phenotype (rare): In the extremely rare mild form of isolated SUOX deficiency, cases have been reported with only childhood intellectual disability and seizures without severe encephalopathy.
The physical and laboratory findings of sulfite oxidase deficiency provide decisive clues for diagnosis.
Neurological signs: In the neonatal period, multifocal seizures (myoclonic seizures, tonic seizures) and sporadic muscle twitching are observed. Eye deviation and abnormal eye movements may accompany them. Hypotonia (neonatal period) → changes to spastic quadriplegia (after several months of age). Deep tendon reflexes: decreased initially, later hyperactive.
Brain imaging findings: On brain MRI diffusion-weighted imaging (DWI), restricted diffusion appears early in the extensive cerebral cortex, basal ganglia (caudate nucleus and putamen), thalamus and brainstem. On T2 images, white matter edema occurs early, followed by progression to cystic change and cerebral atrophy. The cerebellum is relatively preserved early on.
Urine tests: Applying a sulfite test strip (Quantofix Sulfite, or Merck test strip) to fresh urine is positive. This test is very unstable and must be performed immediately upon urine collection. Quantification of urine S-sulfocysteine (SSC) (LC-MS/MS): markedly elevated in patients (undetectable in normal individuals).
Blood tests: Serum uric acid: markedly decreased in MoCD (0–1 mg/dL; normal 3–7 mg/dL). In isolated SUOX deficiency, uric acid is normal, making it an important marker for distinguishing the two forms. Serum amino acids: elevated taurine. Elevated blood S-sulfocysteine.
There is currently no general population screening program for sulfite oxidase deficiency, and the key is immediate testing based on clinical suspicion in patients with intractable neonatal seizures.
Newborn NBS screening (currently not included in most cases): Efforts to include urine S-sulfocysteine in NBS are under way in some countries but have not yet been standardized. Development of dried blood spot–based testing methods is in progress.
Immediate screening based on clinical suspicion: If the following findings are present in the neonatal period, suspect sulfite oxidase deficiency immediately and perform screening tests: ① intractable multifocal seizures occurring within days to weeks of birth (no response to standard anticonvulsants), ② brain MRI shows findings of neonatal hypoxic-ischemic encephalopathy (HIE) or metabolic encephalopathy but there is no history of hypoxia during delivery, ③ markedly decreased serum uric acid (when MoCD is suspected), ④ peculiar urine odor.
Screening test items: Fresh urine sulfite test strip (applied immediately upon collection). Serum uric acid (presence of hypouricemia). Request for quantification of urine and serum S-sulfocysteine. Urine amino acid and organic acid analysis (including differentiation of metabolic seizures).
Family history–based screening: If a previous sibling was diagnosed with sulfite oxidase deficiency, perform prenatal genetic diagnosis (CVS/amniocentesis) in the next pregnancy, and perform an immediate urine sulfite test and genetic testing right after birth.
Definitive diagnosis of sulfite oxidase deficiency is made by quantification of urine S-sulfocysteine and genetic analysis, and the fresh urine sulfite test strip is used for rapid screening.
Fresh urine sulfite test strip: If not performed immediately upon collection (within 15 minutes), it gives a false negative (sulfite decomposes rapidly by oxidation in air). A positive result is confirmed immediately with additional testing.
Quantification of urine S-sulfocysteine (SSC): Quantification of SSC using LC-MS/MS is the key test for definitive diagnosis. SSC is not detected in normal urine and is markedly elevated in patients. SSC is relatively stable and can be analyzed after frozen storage, so it is more reliable than the sulfite test strip.
Serum uric acid: In MoCD, serum uric acid is markedly low at 0–1 mg/dL (uric acid is normal in isolated SUOX deficiency). This finding distinguishes the two forms.
Genetic analysis: Pathogenic variants are confirmed with an NGS-based gene panel (SUOX, MOCS1, MOCS2, GPHN). The genotype classifies the form of MoCD (A/B/C) and identifies candidates for fosdenopterin treatment (MoCD-A).
Urine xanthine and hypoxanthine: Xanthine and hypoxanthine are elevated in MoCD.
Brain MRI: Extensive restricted diffusion early on diffusion-weighted imaging (DWI), followed by cystic encephalomalacia, is characteristic and is used as a finding supporting the diagnosis. MRI findings are similar in isolated SUOX deficiency and MoCD.
Treatment of sulfite oxidase deficiency differs greatly by form, and in MoCD-A fosdenopterin is the only curative drug.
MoCD-A: fosdenopterin (cPMP, Nulibry): An intravenous formulation approved by the FDA in 2021 as a drug designated for priority review for a rare pediatric disease in MoCD-A. It exogenously replaces cPMP (cyclic pyranopterin monophosphate), the intermediate produced by MOCS1 in the Moco synthesis pathway, to restart Moco synthesis and restore SUOX, XDH and AOX activity. Within 1 week of starting administration, improvement in urine and serum sulfite, S-sulfocysteine, xanthine and uric acid levels is seen, and reduced seizures are reported within 2 weeks. Early administration (within 5 days of birth, ideally within 24–48 hours) is decisive for neurodevelopmental prognosis.
Isolated SUOX deficiency and MoCD-B/C: There is currently no effective curative treatment. Attempts to reduce the supply of sulfite precursors with a low-sulfur (low-cystine, low-methionine) diet have been reported in some cases but with limited effect. Supportive care: levetiracetam, phenobarbital and clonazepam for intractable seizures; nutritional support (tube feeding or gastrostomy); rehabilitation (physical, occupational, speech). Vitamin B6 (pyridoxine) supplementation: reduced seizures reported in some (mechanism unclear). Research is under way on xanthine dehydrogenase bypass therapy (pyranopterin delivery mechanism) for MoCD-B.
Gene therapy: AAV-based gene therapy research for correction or replacement of the SUOX and MOCS genes is in progress at the preclinical stage.
The overall prognosis of sulfite oxidase deficiency is very poor, but early treatment with fosdenopterin in MoCD-A has opened the possibility of improved prognosis.
Prognosis of isolated SUOX deficiency and MoCD-B/C: With no effective curative treatment, the prognosis is extremely poor. After acute neonatal encephalopathy, spastic cerebral palsy, severe intellectual disability and intractable seizures persist, and most patients die within several years or reach adulthood in a state requiring total care.
Prognosis of MoCD-A (untreated): In the era before fosdenopterin treatment, the median age at death in MoCD-A was about 2.4 years, and the 1-year survival rate was about 70–77%. Most surviving patients were left with severe spastic cerebral palsy and intellectual disability.
Prognosis of MoCD-A (fosdenopterin treatment): In patients who started early treatment within days to weeks of birth, marked reduction of seizures (resolution in some), mitigation of neurodevelopmental delay and prolonged survival are reported. In an early case (Veldman et al., 2010), seizure freedom and normal neurodevelopment within 2 weeks of starting treatment were reported, and the dramatic effect drew attention. However, when severe brain damage has already occurred before treatment starts, improvement in neurodevelopment is limited.
Importance of the timing of treatment initiation: Early diagnosis (within days of birth) and immediate administration of fosdenopterin are the decisive factors in the prognosis of MoCD-A. Therefore, discussion of including this disease in NBS is very important.
In sulfite oxidase deficiency, the core of prevention is establishing a system for early diagnosis and family genetic counseling, and in MoCD-A, early initiation of treatment determines prognosis.
Primary prevention: Comprehensive genetic counseling and explanation of the recurrence risk (25%) are essential for families who have previously had a child with sulfite oxidase deficiency. Preimplantation genetic testing (PGT-M) or prenatal diagnosis (analysis of the SUOX, MOCS1, MOCS2 and GPHN genes after CVS/amniocentesis) is offered as an option. Particularly because treatment is possible in MoCD-A, counseling on pregnancy planning, including preparation for treatment immediately after birth, is important.
Secondary prevention (early diagnosis through NBS): Methods are being studied that include measurement of urine S-sulfocysteine in newborn screening, or measure serum taurine and SSC by MS/MS. In newborns with a family history, a urine sulfite test strip, quantification of S-sulfocysteine, serum uric acid and a gene panel analysis are performed immediately after birth. Starting fosdenopterin immediately upon confirmation of MoCD-A is decisive for minimizing neurological damage.
Tertiary prevention: In patients who have already been diagnosed, maximize quality of life and functional level through seizure control, nutritional support and rehabilitation. Connection with psychological and social support services for the family and with patient advocacy groups (MoCD/SUOX patient community) is important. Long-term complications are monitored through integrated management by a multidisciplinary team (pediatric neurology, nephrology, nutrition, rehabilitation medicine, genetics).
Veldman A, Santamaria-Araujo JA, Sollazzo S, et al. Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics. 2010;125(5):e1249–e1254. DOI: 10.1542/peds.2009-2192 PMID: 20385638.
Schwahn BC, Van Spronsen FJ, Belaidi AA, et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet. 2015;386(10007):1955–1963. DOI: 10.1016/S0140-6736(15)00124-5 PMID: 26522434.
Schwahn BC, Belaidi AA, Bowhay S, et al. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. J Inherit Metab Dis. 2024;47(1):5–24. DOI: 10.1002/jimd.12730
Leimkuhler S, Charcosset M, Latour P, et al. Ten novel mutations in the molybdenum cofactor genes MOCS1 and MOCS2 and in vitro characterization of a MOCS2 mutation disrupting the binding of cofactor to the active site. Hum Genet. 2005;117(6):565–570. DOI: 10.1007/s00439-005-1350-7 PMID: 16001271.
Johnson JL, Duran M. Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease. 2001:3163–3177.
Abdelfattah-Hassan A, Shalaby AS, El-Kamah GY, et al. Isolated sulfite oxidase deficiency: a review of the literature and report of 2 Egyptian patients. J Pediatr Neurol. 2019;17(1):15–22. DOI: 10.1055/s-0037-1601565
Gourlay LJ, Bhatt D, Bhatt S, et al. Molybdenum cofactor deficiency type A and isolated sulfite oxidase deficiency: clinical and biochemical overview. Orphanet J Rare Dis. 2021;16(1):162. DOI: 10.1186/s13023-021-01744-1
Reiss J, Hahnewald R. Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2. Hum Mutat. 2011;32(1):10–18. DOI: 10.1002/humu.21380 PMID: 21110321.
Hitzert MM, Bos AF, Bergman KA, et al. Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP. Pediatrics. 2012;130(4):e1005–e1010. DOI: 10.1542/peds.2011-3330 PMID: 22966027.
Craciun A, Pham K, Belaidi AA, et al. Outcome of long-term treatment with fosdenopterin (recombinant human MOCS1 enzyme) for type A molybdenum cofactor deficiency. JIMD Rep. 2023;64(4):310–317. DOI: 10.1002/jmd2.12378